Abiraterone is primarily used in the treatment of prostate cancer, specifically in cases where the cancer has become resistant to traditional hormone therapies. It works by inhibiting the production of androgens, which are hormones that can promote the growth of prostate cancer cells. This makes it particularly effective for patients with metastatic castration-resistant prostate cancer (mCRPC).

The medication is often administered in combination with prednisone to enhance its efficacy and to help manage potential side effects. By reducing androgen levels, abiraterone can slow the progression of the disease, alleviate symptoms, and improve overall survival rates. It is typically prescribed after other treatments, such as surgical castration or luteinizing hormone-releasing hormone (LHRH) analogs, have proven insufficient.

Patients undergoing treatment with abiraterone require regular monitoring to assess its effectiveness and to manage any adverse effects, which can include hypertension, fluid retention, and liver function abnormalities. Despite these potential side effects, abiraterone remains a crucial therapeutic option for advanced prostate cancer, offering hope for improved quality of life and extended survival.